HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Government Wants Sildenafil, Tadalafil OTC

Executive Summary

Germany's Ministry of Health surprised all those present at a recent BAH meeting by announcing it would like to see erectile dysfunction drugs like sildenafil and tadalafil available OTC. Such a move, however, would put the government at odds with drug regulator BfArM's Expert Committee for Prescription, which recently rejected an application for the Rx-to-OTC switch of sildenafil. 

You may also be interested in...



Sanofi Feeling Positive On Cialis Switch Progression As Q2 Sales Rise

As Sanofi reports Consumer Healthcare second-quarter sales up by 9%, the company is hopeful it can progress its plan to switch erectile dysfunction drug Cialis in the US following a constructive meeting with the FDA.

Delay For Sanofi’s OTC Cialis Study In US Could Be Sign of Hurdles Holding Back Other Switches

Potential hurdles FDA put in front of Sanofi’s planned tadalafil switch could be sign for agency’s expectations for moving other Rx ingredients to OTC. Sanofi announced its planned actual use trial to support OTC tadalafil use was “placed on clinical hold due to matters surrounding the protocol design.”

Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed

After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel